Payal Jain, graduate PhD student in Dr. Adam Resnick’s lab at the Children’s Hospital of Philadelphia, recently presented an abstract at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics about their therapeutic study on CRAF fusions in pediatric low-grade gliomas. Their findings thus far indicate that unlike pediatric low-grade gliomas (PLGG) that are driven by BRAF fusion proteins, PLGGs that are driven by other forms of RAF fusion proteins, called CRAF fusion proteins, may not respond to single-agent therapy with FDA-approved and investigational RAF inhibitors, suggesting the importance of molecularly stratifying PLGG patients in order to identify appropriate therapies.

As reported by Dr. Jain, PLGGs are “rather poorly studied and loosely categorized…current treatments for PLGGs can be invasive and toxic to children in the long term. Thus, there is a great need to study the genetic and molecular mechanisms driving PLGGs. This would help define novel precision medicine approaches for affected children”.  

The work of this group highlights the ever-growing need and importance of targeted study of the different forms of pediatric brain tumors.  A Kids’ Brain Tumor Cure is proud to continue to fund this cutting- edge research, which brings us one step closer to less toxic treatments and a cure for children with the most common types of brain cancer. We look forward to more positive outcomes from this spectacular team of pediatric brain cancer researchers. Please find the full press release here.